SCHEMBL1964900

SCHEMBL1964900

COC(=O)c1c(O)c2cc(Cl)cn2n(Cc2ccccn2)c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90B1 P14625 3/20 0.46
HSP90AA1 P07900 2/20 0.46
ADRA1D P25100 1/20 0.40
ALDH1A1 P00352 6/20 0.39
TSHR P16473 5/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
KDM4E B2RXH2 4/20 0.39
HPGD P15428 2/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
FEN1 P39748 1/20 0.38
LMNA P02545 3/20 0.38
HTT P42858 3/20 0.38
USP2 O75604 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
MAPT P10636 2/20 0.38
TP53 P04637 1/20 0.38
PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1965863 0.84 EGLN1 (0.45) ALDH1A1TSHRSMN1; SMN2KDM4ELMNA
SCHEMBL1968383 0.83 ALDH1A1 (0.42) ADRA1DALDH1A1TSHRSMN1; SMN2KDM4E
SCHEMBL1968380 0.83 ALDH1A1 (0.42) ADRA1DALDH1A1TSHRSMN1; SMN2KDM4E
SCHEMBL1966780 0.82 MAPT (0.41) HSP90B1HSP90AA1ALDH1A1KDM4EHPGD
SCHEMBL1966356 0.82 AR (0.40) ALDH1A1GAAMAPTPKM
SCHEMBL1966964 0.81 KDM4E (0.47) HSP90B1HSP90AA1ADRA1DALDH1A1TSHR
SCHEMBL1969294 0.79 HSP90AA1 (0.41) HSP90B1HSP90AA1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL1964099 0.79 HSP90B1 (0.41) HSP90B1ALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL1967049 0.75 ADRA1D (0.44) HSP90B1HSP90AA1ADRA1DALDH1A1KDM4E
SCHEMBL3350219 0.73 ADRA1D (0.58) HSP90B1HSP90AA1ADRA1DALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334682-B1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN INC (US) 2017-10-04 EP disclosed
US-8217043-B2 Compounds and methods for their use FIBROGEN, INC. (US) 2012-07-10 US disclosed
EP-2334682-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS Fibrogen, Inc. (US) 2011-06-22 EP disclosed
WO-2010022240-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN, INC. (US) 2010-02-25 WO disclosed
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE FIBROGEN, INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE HIF1AN, HIF1A, EGLN3 HSP90B1 108/4885HSP90AA1 147/4885ADRA1D 3984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.